Boehringer stands by Zealand obesity candidate after weak data
The German drugmaker signals it will keep developing the co-owned obesity asset despite a readout MedWatch describes as disappointing.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 1 08:06 ETSource: medwatch.com
The wire
- 01MedWatch reports Boehringer Ingelheim is continuing to back the obesity drug candidate it partners on with Zealand Pharma following data the outlet characterizes as disappointing.
- 02Boehringer's stance matters to anyone tracking the non-Novo, non-Lilly end of the incretin pipeline, where partner commitment often determines whether an asset advances.
- 03Details of the data and of next development steps were not laid out in the item; watch for Zealand and Boehringer statements and any revised trial plans.
From the source
Read at medwatch.comBoehringer stands by Zealand Pharma’s obesity drug candidate despite disappointing data
